December 1, 2025Physiological ReportsOpen Access

Effect of empagliflozin on human primary cardiomyocytes in a chemically induced hypoxia by CoCl 2

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Analysis shows empagliflozin enhances mitochondrial branching and cell count in cardiomyocytes, suggesting potential benefits for heart failure.

Cell count increased with empagliflozin treatment, indicating enhanced viability and health of cardiomyocytes.
Metabolomic profiling revealed significant metabolic changes in empagliflozin-treated cells related to mitochondrial function.
Observational analysis highlights the cardioprotective role of empagliflozin specifically during hypoxic conditions.
Improvements in mitochondrial branching suggest enhanced cardiovascular outcomes in heart failure models.

Samec et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Analysis shows empagliflozin enhances mitochondrial branching and cell count in cardiomyocytes, suggesting potential benefits for heart failure.